Spain enacted a cancer “right to be forgotten” for insurance/finance after five years clear of recurrence, while EU rules vary by country.
🔗 Read the article on elconfidencial.com
[This is an automatically generated summary, for reference only]
Over 2.5 million cancer cases are diagnosed annually in the European Union, with over 300,000 new cases estimated in Spain this year. Patients face barriers to services like health insurance and mortgages. In response, Spain enacted a “oncological right to be forgotten” in June 2023, allowing individuals who have completed treatment for cancer without recurrence after five years to not disclose their history when applying for insurance or financial products. This is intended to treat the patient as cured. However, this rule has limitations; insurers can still cancel contracts if a subsequent cancer is linked to the previous one. Debates exist regarding chronic cancers and the extent to which private companies must adhere to equality principles compared to public administration. Data shows that 13.9% of cancer survivors in Spain reported issues with private insurance due to their diagnosis. Across Europe, regulations vary; the EU directive allows up to 15 years, while France has set a five-year period post-treatment completion without recurrence. Italy uses a differentiated system based on cancer type and stage, setting varying timeframes for different diagnoses. As of July 2026, only 11 member states had implemented legal measures against financial discrimination against cancer survivors.
